Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05127824 · ClinicalTrials.gov registry record · Phase 2
Autologous Dendritic Cell Vaccine in Kidney Cancer
A Phase 2 study of Carcinoma, Renal Cell, sponsored by Jodi Maranchie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT05127824: Recruiting Phase 2 study of Carcinoma, Renal Cell, sponsored by Jodi Maranchie.
NCT05127824 is a Phase 2 study of Carcinoma, Renal Cell that is actively recruiting participants, run by Jodi Maranchie. The registered enrollment target is 42 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05127824, a Phase 2 study of Carcinoma, Renal Cell, is actively recruiting participants, sponsored by Jodi Maranchie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
Primary Outcome
Proportion of HLA-A2+ ccRCC patients that exhibit improved peripheral blood CD8+ T cell responses against 3 or more vaccine-inclusive peptide epitopes (DLK1, EphA2, HBB, NRP1, RGS5, TEM1) after active vaccination with Type I-polarized autologous dendritic cell (αDC1) vaccine with concomitant oral cabozantinib (IFN-γ ELISPOT).
Conditions Studied
Interventions
- DRUG Cabozantinib
- BIOLOGICAL Autologous alpha-DC1/TBVA vaccine
Study Locations (1)
Pennsylvania
- UPMC Department of Urology - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
What NCT05127824 shows while recruiting
NCT05127824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 2 interventions - of which Cabozantinib is the first listed.
NCT05127824 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05127824 about?
NCT05127824 is a clinical study titled "Autologous Dendritic Cell Vaccine in Kidney Cancer". The purpose of this study is to estimate the probability of immune response for the combination treatment of dendritic cell vaccine with oral cabozantinib and characterize the safety profile of interventional therapy.
What is the current status of trial NCT05127824?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2023-07-06. Estimated completion is 2026-12.
What conditions does trial NCT05127824 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell.
What interventions are being tested in trial NCT05127824?
The interventions under investigation include: Cabozantinib (DRUG), Autologous alpha-DC1/TBVA vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT05127824?
This trial is sponsored by Jodi Maranchie, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05127824 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05127824's enrollment target sits among peer trials
42 25th of 34 higher than 10 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
COMPLETED · Phase 2
-
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI